Kevin Mcnamara Sells 2,000 Shares of Chemed (NYSE:CHE) Stock

Key Points

• CEO Kevin Mcnamara sold 2,000 Chemed shares at an average price of $501.40, generating approximately $1.0 million. His remaining 68,418-share stake declined 2.84%.
• Chemed shares fell 1.3% to $497.63, while the company’s latest quarterly results beat estimates with $6.06 in EPS and $673.25 million in revenue. Management issued fiscal 2026 EPS guidance of $25.00–$25.75.
• Chemed increased its quarterly dividend to $0.70 per share, or $2.80 annually, for a 0.6% yield. Institutional investors own 95.85% of the stock, and analysts maintain a consensus “Hold” rating with a $530.75 average price target.

Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of Chemed stock in a transaction on Friday, September 18th. The shares were sold at an average price of $501.40, for a total value of $1,002,800.00. Following the completion of the sale, the chief executive officer owned 68,418 shares in the company, valued at $34,304,785.20. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Chemed Trading Down 1.3%

Shares of NYSE CHE traded down $6.43 during mid-day trading on Monday, reaching $497.63. 32,582 shares of the company's stock were exchanged, compared to its average volume of 209,088. The company's 50-day moving average is $523.01 and its 200-day moving average is $455.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The firm has a market capitalization of $6.50 billion, a price-to-earnings ratio of 25.04, a PEG ratio of 2.03 and a beta of 0.51. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $557.00.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Analysts expect that Chemed Corporation will post 23.55 EPS for the current fiscal year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 17th. This is a positive change from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is presently 14.06%.

Institutional Investors Weigh In On Chemed

Several hedge funds and other institutional investors have recently made changes to their positions in CHE. BlackRock Inc. purchased a new position in shares of Chemed during the second quarter worth approximately $691,290,000. Norges Bank purchased a new stake in Chemed in the 4th quarter valued at $76,067,000. Bank of America Corp DE purchased a new stake in Chemed in the 2nd quarter valued at $48,255,000. Caisse de depot et placement du Quebec acquired a new stake in Chemed during the 2nd quarter worth $44,309,000. Finally, Bank of New York Mellon Corp acquired a new stake in Chemed during the 2nd quarter worth $43,800,000. Institutional investors and hedge funds own 95.85% of the company's stock.

Wall Street Analyst Weigh In

CHE has been the subject of several recent research reports. Bank of America reiterated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Wall Street Zen cut shares of Chemed from a "strong-buy" rating to a "buy" rating in a report on Saturday. Weiss Ratings upgraded shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, July 17th. Royal Bank Of Canada boosted their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a report on Thursday, July 30th. Finally, Oppenheimer increased their price objective on shares of Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $530.75.

Chemed Company Profile

Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients' homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.

Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.